Anika Therapeutics (ANIK)Director bought ~$20K

~$20K

Approx. value · 1,000 sh @ $20.32

54K

Holds after · shares reported

Traded

Aug 4, 2026

Filed

Aug 5, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Jun 18, 2026Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote“On April 26, 2026, the board of directors, or the Board, of Anika Therapeutics, Inc., or the Company, adopted and approved, subject to stockholder approval, a sixth amendment and restatement of the Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan as previously amended, or the 2017 Plan, and on June 8, 2026, the Board adopted and approved, subject to stockholder approval, a revised sixth amendment and restatement…”
2. Jul 10, 2026Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations
3. Jul 29, 2026Company filing · Form 8-K · ResultsReported its results
4. Aug 3, 2026Insider · Their first buy on recordDirector purchased ~$21K of ANIK shares in the open market
5. Aug 4, 2026 · this disclosureInsiderDirector purchased ~$20K of ANIK shares in the open market

What came next

1. Sep 2, 2026FDAFDA device clearance: HYALOMATRIX
2. Sep 17, 2026FDAFDA device clearance: Integrity Retractable Implant Inserter (6000127)

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Anika Therapeutics

For Anika Therapeutics, OQRO holds 2 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ANIK page.

Other recent filings by Gary P Fischetti, Director

• SEC Form 4 at Anika Therapeutics (ANIK)Aug 5, 2026

The full history of Gary P Fischetti, Director is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Anika Therapeutics

• SEC Form 4Aug 5, 2026
• SEC Form 4May 4, 2026
• SEC Form 4Apr 30, 2026
• House Clerk periodic transaction reportAug 26, 2021
• House Clerk periodic transaction reportAug 26, 2021
• House Clerk periodic transaction reportAug 26, 2021

Everything OQRO holds on this company is on its ANIK page.